Clinical Trial

A Third Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults

Completed
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the performance of NOBO, a yeast-based fermentation product (postbiotic) designed to control axillary odor, in controlling axillary odor in healthy male and female adults age 18 - 70 with confirmed self-perception of body odor. The main question it aims to answer is: Does NOBO decrease self-perceived odor of the intervention axilla compared to the placebo axilla at any time point? Researchers will compare the intervention axilla odor score to the placebo axilla odor score to see if there is a difference in self-perceived odor. Participants will: * be given a NOBO deodorant spray and a placebo deodorant spray (each assigned to one axilla) * self assess body odor * self assess skin irritation
Protocol Amendment History 3 changes
critical Trial completed 2026-08-06
notable Enrollment increased: 14 -> 16 participants 2026-08-06
critical Trial status changed: Enrolling by Invitation → Active, Not Recruiting 2026-08-01
Trial Details
NCT Number NCT07726238
Lead Sponsor Kingdom
Conditions Body Odor
Enrollment 16 participants
Start Date 2026-07-27
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-05